Accretion Pharmaceuticals bulk deals
NSE: ACCPLPharmaceuticals & Biotechnology
Share price at the NSE close on 30 Oct 2026. Previous close ₹181.00.
30 Oct: open ₹188.95, high ₹190.05, low ₹188.95
- Next results date: the board meets on 31 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹211 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 21.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.86
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.23
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,60075.0% delivered
Accretion Pharmaceuticals bulk deals
Last 12 months, since 31 Oct 2025: 2 bulk deals, ₹1.44 Cr bought and none sold Bought and sold in deals. Each deal's shares times its price, added up for the buyers and apart for the sellers, so a block deal, which names both, counts on each side.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Wednesday 29 Apr 20261 firm · ₹0.69 Cr bought · ₹0 soldNet bought ₹0.69 Cr
- BoughtUNICORN FUNDBought 67,200 at ₹102.600.60% of the company₹0.69 Cr
Tuesday 18 Nov 20251 firm · ₹0.75 Cr bought · ₹0 soldNet bought ₹0.75 Cr
- BoughtKHUSHBOO NAHARBought 97,200 at ₹76.790.87% of the company₹0.75 Cr
Wednesday 21 May 20251 firm · ₹0 bought · ₹1.16 Cr soldNet sold ₹1.16 Cr
- SoldGRETEX SHARE BROKING LIMITEDSold 1,40,400 at ₹82.95₹1.16 Cr
A bulk deal is one client trading more than half a per cent of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 3 deals on record since listing on 21 May 2025.